Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Xencor, Inc.
SWOG Cancer Research Network
Hoffmann-La Roche
Emory University
Children's Oncology Group
M.D. Anderson Cancer Center
Massachusetts General Hospital
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Loma Linda University
Memorial Sloan Kettering Cancer Center
Indiana University
UNC Lineberger Comprehensive Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
University of Rochester
Daiichi Sankyo
Indiana University
Seattle Children's Hospital
Seattle Children's Hospital
Assistance Publique - Hôpitaux de Paris
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Children's Oncology Group
Nationwide Children's Hospital
Children's Hospital Medical Center, Cincinnati
Young Adult Survivors United
Sun Yat-sen University
Centre Francois Baclesse
Shandong First Medical University
Shandong First Medical University
Heinrich-Heine University, Duesseldorf
Baylor College of Medicine
National Cancer Institute, Slovakia
University of Texas Southwestern Medical Center
N.N. Petrov National Medical Research Center of Oncology
Turning Point Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
BioNTech SE
Duke University
Gustave Roussy, Cancer Campus, Grand Paris
Cedars-Sinai Medical Center
Hoffmann-La Roche
Indiana University
University Hospital Regensburg
Bambino Gesù Hospital and Research Institute
Alliance for Clinical Trials in Oncology